Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Prostatic Neoplasms 3Leukemia 3Hematologic Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, B-Cell 2Lung Neoplasms 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1

Interventions

Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 4sacituzumab govitecan 3cabozantinib 3atezolizumab 3Taxes 3Paclitaxel 3Nivolumab 3Gemcitabine 3Biopsy 3eribulin 2erdafitinib 2Radiosurgery 2Platinum 2Ipilimumab 2Docetaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1tazemetostat 1sapanisertib 1olaparib 1enfortumab vedotin 1carotuximab 1Tomography, X-Ray Computed 1Suramin 1Panvac-VF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Transitional Cell × Electrocardiography × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡